Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUME-Meso nintedanib plus pemetrexed/cisplatin in unresectable malignant pleural mesothelioma
NL-OMON43431Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pleural mesothelioma comparing Nintedanib arm with Placebo arm (2 arms). Primary endpoint: Progression-free survival. Started Jul 2016; status: active, not recruiting.
02
Drugs
nintedanib
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NL-OMON43431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43431.